Cargando…

Hematopoietic stem cell mobilization with the reversible CXCR4 receptor inhibitor plerixafor (AMD3100)—Polish compassionate use experience

Recent developments in the field of targeted therapy have led to the discovery of a new drug, plerixafor, that is a specific inhibitor of the CXCR4 receptor. Plerixafor acts in concert with granulocyte colony-stimulating factor (G-CSF) to increase the number of stem cells circulating in the peripher...

Descripción completa

Detalles Bibliográficos
Autores principales:	Basak, Grzegorz Wladyslaw, Knopinska-Posluszny, Wanda, Matuszak, Magdalena, Kisiel, Elzbieta, Hawrylecka, Dorota, Szmigielska-Kaplon, Anna, Urbaniak-Kujda, Donata, Dybko, Jaroslaw, Zielinska, Patrycja, Dabrowska-Iwanicka, Anna, Werkun, Joanna, Rzepecki, Piotr, Wroblewska, Wiktoria, Wiktor-Jedrzejczak, Wieslaw
Formato:	Texto
Lenguaje:	English
Publicado:	Springer-Verlag 2010
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3070880/ https://www.ncbi.nlm.nih.gov/pubmed/20938660 http://dx.doi.org/10.1007/s00277-010-1098-7

Ejemplares similares

Mozobil® (Plerixafor, AMD3100), 10 years after its approval by the US Food and Drug Administration
por: De Clercq, Erik
Publicado: (2019)

AMD3100/CXCR4 Inhibitor
por: De Clercq, Erik
Publicado: (2015)

The CXCR4 antagonist plerixafor (AMD3100) promotes proliferation of Ewing sarcoma cell lines in vitro and activates receptor tyrosine kinase signaling
por: Berning, Philipp, et al.
Publicado: (2018)

Influence of CYP2C19*2/*17 genotype on adverse drug reactions of voriconazole in patients after allo-HSCT: a four-case report
por: Beata, Sienkiewicz, et al.
Publicado: (2017)

Abstract 40: AMD3100 (Plerixafor) As A Single-Dose Stem Cell Mobilizing Agent In Vascularized Composite Tissue Allograft (VCA) Transplantation In A Canine Model
por: Swearingen, Bruce J., et al.
Publicado: (2018)

Durable response of glioblastoma to adjuvant therapy consisting of temozolomide and a weekly dose of AMD3100 (plerixafor), a CXCR4 inhibitor, together with lapatinib, metformin and niacinamide
por: Rios, Adan, et al.
Publicado: (2016)

Influence of CYP2C19 Genotypes on the Occurrence of Adverse Drug Reactions of Voriconazole among Hematological Patients after Allo-HSCT
por: Sienkiewicz, Beata, et al.
Publicado: (2017)

Abstract 47: AMD3100 (Plerixafor) As A Single-Dose Stem Cell Mobilizing Agent In Vascularized Composite Tissue Allograft (VCA) Transplantation In A Canine DLA-Mismatch Model
por: Swearingen, Bruce J., et al.
Publicado: (2019)

MOBILIZATION STUDIES IN COMPLEMENT-DEFICIENT MICE REVEAL THAT OPTIMAL AMD3100 MOBILIZATION OF HEMATOPOIETIC STEM CELLS DEPENDS ON COMPLEMENT CASCADE ACTIVATION BY AMD3100-STIMULATED GRANULOCYTES
por: Lee, HakMo, et al.
Publicado: (2009)

AMD3100 sensitizes acute lymphoblastic leukemia cells to chemotherapy in vivo
por: Yu, M, et al.
Publicado: (2011)

Fecal microbiota transplantation in the treatment of intestinal steroid-resistant graft-versus-host disease: two case reports and a review of the literature
por: Biernat, Monika Maria, et al.
Publicado: (2020)

CXCR4 Antagonist AMD3100 Accelerates Impaired Wound Healing in Diabetic Mice
por: Nishimura, Yukihide, et al.
Publicado: (2011)

Combinatorial G-CSF/AMD3100 Treatment in Cardiac Repair after Myocardial Infarction
por: Rüder, Constantin, et al.
Publicado: (2014)

Treatment with AMD3100 attenuates the microglial response and improves outcome after experimental stroke
por: Walter, Helene L, et al.
Publicado: (2015)

VEGF with AMD3100 endogenously mobilizes mesenchymal stem cells and improves fracture healing
por: Meeson, Richard, et al.
Publicado: (2018)

The Hasford Score May Predict Molecular Response in Chronic Myeloid Leukemia Patients: A Single Institution Experience
por: Dybko, Jarosław, et al.
Publicado: (2016)

Alpha-tocopherol succinate- and AMD3100-mobilized progenitors mitigate radiation combined injury in mice
por: Singh, Vijay K., et al.
Publicado: (2014)

AMD3100 inhibits the migration and differentiation of neural stem cells after spinal cord injury
por: Liu, Jia-Ming, et al.
Publicado: (2017)

Functional Phenotypes of Peritoneal Macrophages Upon AMD3100 Treatment During Colitis-Associated Tumorigenesis
por: Wu, Shuai, et al.
Publicado: (2022)

CXCR4 Antagonist AMD3100 Modulates Claudin Expression and Intestinal Barrier Function in Experimental Colitis
por: Xia, Xian-Ming, et al.
Publicado: (2011)

The CXCR4 Antagonist AMD3100 Has Dual Effects on Survival and Proliferation of Myeloma Cells In Vitro
por: Kim, Ha-Yon, et al.
Publicado: (2010)

[(18)F]DPA-714 PET Imaging of AMD3100 Treatment in a Mouse Model of Stroke
por: Wang, Yu, et al.
Publicado: (2014)

AMD3100 improves ovariectomy-induced osteoporosis in mice by facilitating mobilization of hematopoietic stem/progenitor cells
por: Im, Jin Young, et al.
Publicado: (2014)

Effect of Endogenous Bone Marrow Derived Stem Cells Induced by AMD-3100 on Expanded Ischemic Flap
por: Jeong, Hii-Sun, et al.
Publicado: (2014)

Administration of AMD3100 in endotoxemia is associated with pro-inflammatory, pro-oxidative, and pro-apoptotic effects in vivo
por: Seemann, Semjon, et al.
Publicado: (2016)

Circulating sCD138 and Some Angiogenesis-Involved Cytokines Help to Anticipate the Disease Progression of Early-Stage B-Cell Chronic Lymphocytic Leukemia
por: Wołowiec, Dariusz, et al.
Publicado: (2006)

Plerixafor
por: Slater, Susan
Publicado: (2012)

Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist
por: Broxmeyer, Hal E., et al.
Publicado: (2005)

Effectiveness of AMD3100 in treatment of leukemia and solid tumors: from original discovery to use in current clinical practice
por: Liu, Tao, et al.
Publicado: (2016)

CXCR4 Antagonist AMD3100 Reverses the Resistance to Tamoxifen in Breast Cancer via Inhibiting AKT Phosphorylation
por: Zhou, Jun, et al.
Publicado: (2020)

Inhibition of CXCR4 in Spinal Cord and DRG with AMD3100 Attenuates Colon-Bladder Cross-Organ Sensitization
por: Zhang, Hengshuai, et al.
Publicado: (2022)

BKV Related Hemorrhagic Cystitis—An Insight into Risk Factors and Later Complications—An Analysis on Behalf of Polish Adult Leukemia Group
por: Dybko, Jarosław, et al.
Publicado: (2022)

Selective Enhancement of Donor Hematopoietic Cell Engraftment by the CXCR4 Antagonist AMD3100 in a Mouse Transplantation Model
por: Kang, Yubin, et al.
Publicado: (2010)

MicroRNA-146a and AMD3100, two ways to control CXCR4 expression in acute myeloid leukemias
por: Spinello, I, et al.
Publicado: (2011)

Synthesis and Evaluation of [(67)Ga]-AMD3100: A Novel Imaging Agent for Targeting the Chemokine Receptor CXCR4
por: Aghanejad, Ayuob, et al.
Publicado: (2014)

CXCR4 inhibition with AMD3100 attenuates amphetamine induced locomotor activity in adolescent Long Evans male rats
por: Mason, Briana, et al.
Publicado: (2021)

V3-Independent Competitive Resistance of a Dual-X4 HIV-1 to the CXCR4 Inhibitor AMD3100
por: Maeda, Yosuke, et al.
Publicado: (2014)

Chronic administration of AMD3100 increases survival and alleviates pathology in SOD1(G93A) mice model of ALS
por: Rabinovich-Nikitin, Inna, et al.
Publicado: (2016)

C-X-C-Chemokine-Receptor-Type-4 Inhibitor AMD3100 Attenuates Pulmonary Inflammation and Fibrosis in Silicotic Mice
por: Sun, Qixian, et al.
Publicado: (2022)

HuR-targeted nanotherapy in combination with AMD3100 suppresses CXCR4 expression, cell growth, migration, and invasion in lung cancer
por: Muralidharan, Ranganayaki, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_lrhvb9l5dataubmrdkq3mqiujv